Positive results from a trial of Oncotype DX breast cancer diagnostics- Genomic Health
Genomic Health announced that, in addition to the positive five-year results from a group of patients with low Oncotype DX Recurrence Score results from the watershed ECOG-ACRIN Cancer Research Group's TAILORx study, published in The New England Journal of Medicine, two additional positive international Oncotype DX clinical outcomes studies were presented at the 2015 European Cancer Congress.
Reinforcing the published findings from TAILORx, two additional Oncotype DX clinical outcomes studies included positive results from a large, multi-center cohort from Clalit Health Services in Israel with follow-up exceeding 5 years, and a separate study of prospective survival results from the WSG Phase III Plan B trial in Germany.
See: Prospective Validation of a 21-Gene Expression Assay in Breast Cancer. Sparano JA, Gray RJ, Makower DF, Pritchard KI, Albain KS, Hayes DF, et al. N Engl J Med. 2015 Sep 27. DOI: 10.1056/NEJMoa1510764
Comment: An earlier study suggests that an experimental genomic test called PAM50 done on early-stage, hormone-receptor-positive breast cancer that’s been treated with hormonal therapy offers more information on a woman’s risk of recurrence than the Oncotype DX genomic test and the IHC4 test. The PAM50 test may estimate the risk of distant recurrence (the cancer coming back in a part of the body away from the breast) better than both of the other tests for some women. The study was published online on 1 July 2013 by the Journal of Clinical Oncology.
See: Comparison of PAM50 risk of recurrence score with oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapy. Dowsett M, Sestak I, Lopez-Knowles E, Sidhu K, Dunbier AK, Cowens JW, Ferree S, Storhoff J, Schaper C, Cuzick J. J Clin Oncol. 2013;31:2783-90. DOI:
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.